EA031182B1 - Ang2-связывающие молекулы - Google Patents

Ang2-связывающие молекулы Download PDF

Info

Publication number
EA031182B1
EA031182B1 EA201401065A EA201401065A EA031182B1 EA 031182 B1 EA031182 B1 EA 031182B1 EA 201401065 A EA201401065 A EA 201401065A EA 201401065 A EA201401065 A EA 201401065A EA 031182 B1 EA031182 B1 EA 031182B1
Authority
EA
Eurasian Patent Office
Prior art keywords
amg386
vhh
inappropriate
ang2
amino acid
Prior art date
Application number
EA201401065A
Other languages
English (en)
Russian (ru)
Other versions
EA201401065A1 (ru
Inventor
Эрик Боргес
Андреас Гшвинд
Рене Георг Отт
Мари-Анже Бюйзе
Йоахим Букно
Паскаль Мершьер
Эрик Депла
Фредерик Стевенарт
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA031182(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201401065A1 publication Critical patent/EA201401065A1/ru
Publication of EA031182B1 publication Critical patent/EA031182B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA201401065A 2012-03-30 2013-03-27 Ang2-связывающие молекулы EA031182B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12162615 2012-03-30
PCT/EP2013/056635 WO2013144266A1 (en) 2012-03-30 2013-03-27 Ang2-binding molecules

Publications (2)

Publication Number Publication Date
EA201401065A1 EA201401065A1 (ru) 2015-03-31
EA031182B1 true EA031182B1 (ru) 2018-11-30

Family

ID=48190468

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201401065A EA031182B1 (ru) 2012-03-30 2013-03-27 Ang2-связывающие молекулы

Country Status (27)

Country Link
US (5) US20130259859A1 (enExample)
EP (1) EP2831111B1 (enExample)
JP (1) JP5970734B2 (enExample)
KR (1) KR102020255B1 (enExample)
CN (1) CN104321344B (enExample)
AU (1) AU2013241769B2 (enExample)
BR (1) BR112014023415B1 (enExample)
CA (1) CA2865464C (enExample)
CL (1) CL2014002393A1 (enExample)
CY (1) CY1122007T1 (enExample)
DK (1) DK2831111T3 (enExample)
EA (1) EA031182B1 (enExample)
ES (1) ES2729165T3 (enExample)
HR (1) HRP20190817T1 (enExample)
HU (1) HUE044263T2 (enExample)
IL (1) IL234234B (enExample)
IN (1) IN2014DN06904A (enExample)
LT (1) LT2831111T (enExample)
MX (1) MX350248B (enExample)
NZ (1) NZ628584A (enExample)
PH (1) PH12014502179B1 (enExample)
PL (1) PL2831111T3 (enExample)
PT (1) PT2831111T (enExample)
RS (1) RS58732B1 (enExample)
SI (1) SI2831111T1 (enExample)
TR (1) TR201908638T4 (enExample)
WO (1) WO2013144266A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
EP3207059A1 (en) 2014-10-17 2017-08-23 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
AU2016239949A1 (en) * 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
RU2749674C2 (ru) 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь
WO2018071824A1 (en) * 2016-10-13 2018-04-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
KR102143132B1 (ko) * 2016-12-26 2020-08-10 기초과학연구원 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
BR112019022074A2 (pt) * 2017-06-02 2020-05-12 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer
CN108659130B (zh) * 2018-05-28 2021-09-10 长春力太生物技术有限公司 一种抗癌胚抗原纳米抗体及其应用
JP2021529557A (ja) 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
WO2021178209A1 (en) * 2020-03-03 2021-09-10 Aptitude Medical Systems, Inc. Aptamers and use thereof
CN111875706B (zh) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 一种抗人IgE蛋白的单域抗体及其应用
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
EP4400512A4 (en) * 2021-09-10 2025-07-23 Soter Biopharma Pte Ltd ANTI-ANG2 ANTIBODY, ITS PREPARATION METHOD AND ITS USE
JP2025533028A (ja) 2022-09-28 2025-10-03 科▲興▼生物制▲薬▼股▲ふん▼有限公司 Ａｎｇ－２を認識できる抗体または抗原結合断片及びｖｅｇｆとａｎｇ－２を同時に認識できる二重抗体
CN115819592B (zh) * 2022-12-27 2026-04-24 上海医药集团生物治疗技术有限公司 靶向ror1的抗原结合蛋白
WO2025117641A2 (en) * 2023-12-01 2025-06-05 Tavotek Biotherapeutics (Hong Kong) Limited ANTIBODIES TARGETING DISEASE ASSOCIATED ANTIGEN AND γδ T CELL RECEPTORS AND USES THEREOF
WO2025137089A1 (en) * 2023-12-19 2025-06-26 Beam Therapeutics Inc. Cd19-binding polypeptides, compositions comprising the same, and methods for use thereof
WO2026016001A1 (en) * 2024-07-15 2026-01-22 Quaerite Biopharm Research (Beijing) Co., Ltd. Anti-ang2 monospecific and multispecific antibody constructs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147248A2 (en) * 2008-06-05 2009-12-10 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2010066836A2 (en) * 2008-12-10 2010-06-17 Ablynx Nv Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US20110027286A1 (en) * 2009-07-29 2011-02-03 Regeneron Pharmaceuticals, Inc. High Affinity Human Antibodies to Human Angiopoietin-2

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1361892A4 (en) 2001-01-17 2004-10-13 Trubion Pharmaceuticals Inc BINDING DOMAIN FUSION PROTEIN Immunoglobulin
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
JP2009539870A (ja) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CN101663319A (zh) 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147248A2 (en) * 2008-06-05 2009-12-10 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2010066836A2 (en) * 2008-12-10 2010-06-17 Ablynx Nv Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US20110027286A1 (en) * 2009-07-29 2011-02-03 Regeneron Pharmaceuticals, Inc. High Affinity Human Antibodies to Human Angiopoietin-2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARTER P J: "POTENT ANTIBODY THERAPEUTICS BY DESIGN", NATURE REVIEWS IMMUNOLOGY, NATURE PUB. GROUP, GB, vol. 6, 7 April 2006 (2006-04-07), GB, pages 343 - 357, XP007901440, ISSN: 1474-1733, DOI: 10.1038/nri1837 *
REVETS H, BAETSELIER DE P, MUYLDERMANS S: "NANOBODIES AS NOVEL AGENTS FOR CANCER THERAPY", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, ASHLEY, LONDON; GB, vol. 5, no. 1, 1 January 2005 (2005-01-01), ASHLEY, LONDON; GB, pages 111 - 124, XP009076361, ISSN: 1471-2598, DOI: 10.1517/14712598.5.1.111 *
WARK, K.L. ; HUDSON, P.J.: "Latest technologies for the enhancement of antibody affinity", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 58, no. 5-6, 7 August 2006 (2006-08-07), AMSTERDAM, NL, pages 657 - 670, XP024892147, ISSN: 0169-409X, DOI: 10.1016/j.addr.2006.01.025 *

Also Published As

Publication number Publication date
PH12014502179A1 (en) 2014-12-10
EA201401065A1 (ru) 2015-03-31
US20230203146A1 (en) 2023-06-29
HUE044263T2 (hu) 2019-10-28
JP2015516805A (ja) 2015-06-18
BR112014023415B1 (pt) 2022-04-12
CL2014002393A1 (es) 2015-01-23
CA2865464A1 (en) 2013-10-03
TR201908638T4 (tr) 2019-07-22
DK2831111T3 (en) 2019-04-29
IN2014DN06904A (enExample) 2015-05-15
AU2013241769A1 (en) 2014-08-28
PT2831111T (pt) 2019-05-31
CY1122007T1 (el) 2020-10-14
CA2865464C (en) 2022-07-12
RS58732B1 (sr) 2019-06-28
SI2831111T1 (sl) 2019-06-28
JP5970734B2 (ja) 2016-08-17
NZ628584A (en) 2016-04-29
ES2729165T3 (es) 2019-10-30
WO2013144266A1 (en) 2013-10-03
US20190135907A1 (en) 2019-05-09
CN104321344A (zh) 2015-01-28
US20200207845A1 (en) 2020-07-02
US20130259859A1 (en) 2013-10-03
IL234234B (en) 2020-06-30
KR102020255B1 (ko) 2019-09-10
MX350248B (es) 2017-08-31
CN104321344B (zh) 2017-11-21
EP2831111A1 (en) 2015-02-04
MX2014011171A (es) 2015-03-06
HRP20190817T1 (hr) 2019-06-28
PH12014502179B1 (en) 2014-12-10
AU2013241769B2 (en) 2017-05-11
EP2831111B1 (en) 2019-03-20
BR112014023415A2 (pt) 2017-07-11
LT2831111T (lt) 2019-05-10
US20170107281A1 (en) 2017-04-20
PL2831111T3 (pl) 2019-09-30
KR20140146606A (ko) 2014-12-26

Similar Documents

Publication Publication Date Title
US20230203146A1 (en) Ang2-binding molecules
JP5979504B2 (ja) Ｖｅｇｆ結合分子
US20110195494A1 (en) Dll4-binging molecules
TWI535735B (zh) 結合ｄｌｌ４及ａｎｇ２之雙特異性結合分子
KR20120101375A (ko) 항-혈관형성 치료를 위한 이중 특이적 결합 분자
AU2020242704A1 (en) Bispecific antibody specifically bound to VEGF and ANG2
HK1171031A (en) Dll4-binding molecules
HK1190735A (en) Bispecific binding molecules binding to d114 and ang2
TW201305202A (zh) Ｖｅｇｆ－結合分子

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM